17.20

6.06% 1.0322

Arcturus Therapeutics Holdings Inc (ARCT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$16.17

Aprire:

$16.22

Volume 24 ore:

239.23K

Relative Volume:

0.64

Capitalizzazione di mercato:

$446.40M

Reddito:

$157.75M

Utile/perdita netta:

$-29.73M

Rapporto P/E:

5.7532

EPS:

2.99

Flusso di cassa netto:

$-21.00M

1 W Prestazione:

-6.49%

1M Prestazione:

-17.86%

6M Prestazione:

-42.55%

1 anno Prestazione:

-25.24%

Intervallo 1D:

$15.50

$17.23

Intervallo di 1 settimana:

$14.93

$18.09

Portata 52W:

$14.93

$45.00

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

Nome

Arcturus Therapeutics Holdings Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

(858) 900-2660

Indirizzo

10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA

Dipendente

180

Cinguettio

@ArcturusRx

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

ARCT's Discussions on Twitter

Confronta ARCT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ARCT	17.22	446.40M	157.75M	-29.73M	-21.00M	2.99
VRTX	450.00	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	748.66	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	588.46	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.13	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	106.50	24.89B	3.30B	-501.07M	1.03B	11.54

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-07-24	Iniziato	William Blair	Outperform
2023-05-11	Aggiornamento	H.C. Wainwright	Neutral → Buy
2022-11-14	Ripresa	Wells Fargo	Overweight
2022-11-10	Downgrade	Robert W. Baird	Neutral → Underperform
2022-11-03	Aggiornamento	Citigroup	Neutral → Buy
2022-11-02	Aggiornamento	Barclays	Underweight → Equal Weight
2022-08-10	Downgrade	Raymond James	Mkt Perform → Underperform
2022-07-19	Ripresa	Cantor Fitzgerald	Overweight
2022-05-11	Aggiornamento	Robert W. Baird	Underperform → Neutral
2022-04-21	Downgrade	Citigroup	Buy → Neutral
2022-01-31	Aggiornamento	Raymond James	Underperform → Mkt Perform
2021-08-12	Downgrade	Raymond James	Mkt Perform → Underperform
2021-08-11	Downgrade	Goldman	Neutral → Sell
2021-08-10	Downgrade	Robert W. Baird	Neutral → Underperform
2021-07-02	Iniziato	Cantor Fitzgerald	Overweight
2021-06-25	Ripresa	Goldman	Neutral
2021-06-21	Downgrade	Barclays	Equal Weight → Underweight
2021-06-04	Ripresa	Robert W. Baird	Neutral
2021-02-17	Downgrade	B. Riley Securities	Neutral → Sell
2021-01-19	Downgrade	B. Riley Securities	Buy → Neutral
2021-01-15	Downgrade	B. Riley Securities	Buy → Neutral
2021-01-07	Iniziato	Wells Fargo	Overweight
2020-12-29	Downgrade	Barclays	Overweight → Equal Weight
2020-12-29	Downgrade	H.C. Wainwright	Buy → Neutral
2020-12-29	Downgrade	Raymond James	Outperform → Mkt Perform
2020-12-29	Downgrade	Robert W. Baird	Outperform → Neutral
2020-12-23	Downgrade	ROTH Capital	Buy → Sell
2020-12-08	Reiterato	B. Riley Securities	Buy
2020-12-07	Reiterato	B. Riley Securities	Buy
2020-10-26	Iniziato	Barclays	Overweight
2020-10-06	Iniziato	Citigroup	Buy
2020-08-26	Iniziato	Piper Sandler	Overweight
2020-07-30	Ripresa	ROTH Capital	Buy
2020-07-16	Iniziato	Raymond James	Outperform
2020-07-13	Iniziato	B. Riley FBR	Buy
2020-06-09	Downgrade	WBB Securities	Buy → Hold
2020-02-11	Iniziato	Robert W. Baird	Outperform
2020-02-07	Iniziato	Guggenheim	Buy
2020-02-06	Iniziato	Guggenheim	Buy
2019-04-05	Iniziato	H.C. Wainwright	Buy
2018-09-20	Aggiornamento	WBB Securities	Buy → Strong Buy
2018-01-22	Iniziato	Chardan Capital Markets	Buy

Mostra tutto

Arcturus Therapeutics Holdings Inc Borsa (ARCT) Ultime notizie

Nov 18, 2024

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference - Yahoo Finance

Nov 18, 2024

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | ARCT Stock News - StockTitan

Nov 18, 2024

Nov 16, 2024

Sumitomo Mitsui Trust Group Inc. Buys 712,650 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat

Nov 16, 2024

Nov 15, 2024

Avian Flu: FDA Authorizes Self-Replicating Vaccine Trial to Bill Gates-Backed Company, "Study Can Proceed" - presskit.it

Nov 15, 2024

Nov 14, 2024

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data (NASDAQ:ARCT) - Seeking Alpha

Nov 14, 2024

Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production | ARCT Stock News - StockTitan

Nov 14, 2024

Nov 12, 2024

Arcturus gains IND clearance for H5N1 influenza sa-RNA vaccine candidate - BioWorld Online

Nov 12, 2024

Possible Signal As Arcturus Therapeutics Holdings Insiders Sell US$1.6m In Stock - Simply Wall St

Nov 12, 2024

Another Avian Influenza mRNA Vaccine Candidate Advances - Precision Vaccinations

Nov 12, 2024

Nov 11, 2024

Arcturus Gets FDA Green Light for H5N1 Flu mRNA Vaccine Trial, Backed by BARDA | ARCT Stock News - StockTitan

Nov 11, 2024

What is HC Wainwright's Estimate for ARCT FY2028 Earnings? - MarketBeat

Nov 11, 2024

Arcturus Therapeutics’ (ARCT) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 11, 2024

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial - Business Wire

Nov 11, 2024

Nov 09, 2024

Earnings call: Arcturus Therapeutics reported a net loss of $6.9 million - Investing.com Australia

Nov 09, 2024

Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 09, 2024

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Nov 08, 2024

Nikko Asset Management Americas, Inc. Expands Stake in Arcturus Therapeutics Holdings Inc. - GuruFocus.com

Nov 08, 2024

Arcturus Therapeutics (NASDAQ:ARCT) Receives "Buy" Rating from HC Wainwright - MarketBeat

Nov 08, 2024

ARK Investment Management LLC Has $48.77 Million Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat

Nov 08, 2024

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Average Target Price from Brokerages - Defense World

Nov 08, 2024